Table 3 Choice and efficacy of third line H. pylori eradication.
From: Efficacy of Helicobacter pylori eradication therapies: a single centre observational study
Resistance pattern | Regimen | Number of | Successfully | Percent |
|---|---|---|---|---|
patients | treated | success | ||
(95% CI) | ||||
Met – Res | 14 days | |||
Clarith – Res | omeprazole 20 mg bid | 10 | 6 | 60% |
rifabutin 300 mg od | (30–90%) | |||
amoxicillin 1 g bid | ||||
Met – Res | 14 days | |||
Clarith – Sens | RBC 400 mg bid | 5 | 4 | 80% |
clarithromycin 500 mg | (45–100%) | |||
bid | ||||
tetracycline 1 g bid | ||||
Met – Sens | 14 days | |||
Clarith – Res | RBC 400 mg bid | 1 | 1 | 100% |
tinidazole 500 mg bid | - | |||
tetracycline 1 g bid | ||||
Unknown | 14 days | |||
omeprazole 20 mg bid | 4 | 2 | 50% | |
rifabutin 300 mg od | (1–99%) | |||
amoxicillin 1 g bid |